Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring System.

At-home patient self-monitoring of warfarin therapy yielded similar results to monitoring performed in a clinic setting and randomized trials, particularly among those who self-tested on a weekly ...

This recall does not affect the strips used by self-testers at home for INR monitoring (PN 100071). Alere is conducting a thorough investigation into the cause for these events.

WALTHAM, Mass., Dec. 8, 2014 /PRNewswire/ -- Alere Inc. has initiated a voluntary correction to inform U.S. users of the Alere INRatio (R) and INRatio (R)2 PT/INR Monitor system of certain medical ...

A leading provider of health management services, Alere is now offering its At-Home Blood Pressure (BP) Monitoring program to CAD care management patients as a value-added service for health plan ...

WALTHAM, Mass. - Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. (NYSE:ALR) will be initiating a voluntary withdrawal of the Alere INRatio and ...

The Alere INRatio and INRatio2 PT/INR monitoring systems will be withdrawn from the market because of the potential for the monitors to give inaccurate INR results.

OTTAWA , July 16, 2016 /CNW/ - The issue: Alere Inc. is withdrawing the Alere INRatio ® and INRatio ® 2 Prothrombin Time Monitoring Systems (professional and self-test) ...

The voluntary recall does not include the Alere INRatio PT/INR Test Strip (PN 100071), which is utilized by patient self-testers for home INR monitoring.

Real-world retrospective analysis of over 29,000 patients performing INR home monitoring for warfarin therapy shows excellent time in therapeutic range.